Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

July 20, 2021

Primary Completion Date

March 1, 2023

Study Completion Date

March 20, 2026

Conditions
Rectal Cancer
Interventions
COMBINATION_PRODUCT

Short course radiotherapy sequential camrelizumab and chemotherapy

Short course radiotherapy, 5 \* 5Gy, once a day, 5Gy each time, for 5 days, continuous irradiation, three-dimensional 3D-CRT or IMRT technology is recommended camrelizumab 200 mg , D1, intravenous drip, q3w, 2 cycles before operation, postoperative adjuvant treatment, the longest medication time of camrelizumab was less than 1 year during the whole study period; Capecitabine 1000 mg / m2, twice a day, oral, 1-14 days, then rest for 7 days, q3w, 2 cycles before operation and 6 cycles after operation; Oxaliplatin 130 mg / m2, D1, intravenous infusion 2 hours, q3w, 2 cycles before operation, 6 cycles after operation

Trial Locations (1)

Unknown

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER